Inhibitors of dipeptidyl peptidase I
The present invention relates to specific inhibitors of the cysteine protease dipeptidyl peptidase I (DP I), which can be used in the treatment of malignant cell degeneration, immune deseases impaired wound healing and metabolic diseases of humans and are represented by the general formula in which R is a peptide or a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, a C 3 -C 9 cycloalkyl, C 4 -C 9 carbocyclic, C 5 -C 14 aryl, C 3 -C 9 heteroaryl, C 3 -C 9 heterocyclic, all of the above residues optionally being substituted, the residue AS—AS is a dipeptide or a mimetic thereof, AS is an amino acid or a peptide mimetic thereof. The amino acid is peptide bound with R and R′ is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, a C 3 -C 9 cycloalkyl, C 4 -C 9 cycloalkenyl, C 2 -C 9 heterocycloalkyl, C 3 -C 9 heterocycloalkenyl, C 5 -C 14 aryl, C 3 -C 9 heteroaryl, C 3 -C 9 heterocyclic, whereas the heterocycloalkyl, heterocycloalkenyl, heteroaryl, heterocyclic residue can have up to 6 hetero ring atoms, an amino acid or a peptide mimetic thereof, all of the above residues may be optionally substituted, or is H.
1. Compounds of the general formula (I)
wherein
R is a peptide or a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, a C 3 -C 9 cycloalkyl, C 4 -C 9 carbocyclic, C 5 -C 14 aryl, C 3 -C 9 heteroaryl, or C 3 -C 9 heterocyclic, all of the above residues optionally being substituted, the residue AS—AS is a dipeptide or a mimetic thereof,
E is O or S, and
R′ is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, a C 3 -C 9 cycloalkyl, C 4 -C 9 cycloalkenyl, C 2 -C 9 heteracycloalkyl, C 3 -C 9 heterocycloalkenyl, C 5 -C 14 aryl, C 3 -C 9 heteroaryl, or C 3 -C 9 heterocyclic, wherein the heterocycloalkyl, heterocycloalkenyl, heteroaryl, heterocyclic residue can have up to 6 hetero atoms in the ring, or R′ is an amino acid or a peptide or a mimetic thereof, all of the above residues optionally being substituted, or R′ is H or alkoxy, alkenyloxy, alkynyloxy, carbocyclicoxy, heteroraryloxy, heterocyclicoxy, thioether or a substituted residue thereof.
2. Compounds of the general formula (I)
wherein R is phenyl or naphthyl optionally mono-, di-, or poly-substituted by C 1 -C 6 alkoxy, C 1 -C 6 alkyl, C 2 -C 6 alkyenyloxy, C 2 -C 6 alkynyloxy, C 3 -C 9 heterocycloxy, C 3 -C 9 heterocylicoxy, C 1 -C 6 thioether or a substituted residue thereof, NO 2 , NH 2 , F, Cl, Br, I atoms or groups, AS—AS is a dipeptide or a mimetic thereof,
E is O or S, and
R′ is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, a C 3 -C 9 cycloalkyl, C 4 -C 9 cycloalkenyl, C 2 -C 9 heterocycloalkyl, C 3 -C 9 heterocycloalkenyl, C 5 -C 14 aryl, C 3 -C 9 heteroaryl, C 3 -C 9 heterocyclic, wherein the heterocycloalkyl, heterocycloalkenyl, heteroaryl, heterocyclic residue an have up to 6 hetero atoms in the ring, or R′ is an amino acid or a peptide or mimetic thereof, all of the above residues optionally being substituted, or R′ is H or alkoxy, alkenyloxy, alkynyloxy, carbocyclicoxy, heteroraryloxy, heterocyclicoxy, thioether or a substituted residue thereof.
3. Compounds according to claim 1 , wherein R′ is a phenyl or naphthyl.
4. Compounds according to claim 1 , wherein R′ is
wherein V is N or CH and n=1-6.
5. Compounds according to claim 1 or 2 , wherein R′ is
wherein T 1 is CH or N,
W 1 , X 1 , Y 1 and Z 1 are independently from each other selected from CH 2 , NR 2 , N + (R 3 ) 2 , O, S, SO, S(R 4 ) 2 , or SO 2 , with the proviso that at least two of W 1 , X 1 , Y 1 and Z 1 are CH 2 -groups, R 2 , R 3 and R 4 are independently from each other a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3 -C 9 cycloalkyl, C 4 -C 9 cycloalkenyl or H.
6. Compounds according to claim 1 , wherein R′ is
wherein T 2 is C or N + ,
W 2 , X 2 , Y 2 and Z 2 are independently from each other selected from CH, N, N + R 5 or S + R 6 , R 5 and R 6 are independently from each other a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3 -C 9 cycloalkyl, C 4 -C 9 cycloalkenyl or H.
7. Compounds according to claim 1 , wherein R′ is
wherein T 3 , W 3 , X 3 , Y 3 and Z 3 are independently from each other are selected from CH, N + R 7 or S + R 8 , R 7 and R 8 are independently from each other a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, C 3 -C 9 cycloalkyl, C 4 -C 9 cycloalkenyl or H.
8. Compounds according to claim 1 , wherein R′ is
wherein T 4 is C or N + .
9. Compounds according to claim 1 , wherein R′ is an amino acid, a peptide, a dipeptide or a mimetic thereof.
10. Compounds according to claim 1 , wherein the residue R′ may be mono-, di-, or poly-substituted by C 1 -C 6 alkoxy, C 1 -C 6 alkyl, C 1 -C 6 thioether, NO 2 , NH 2 , F, Cl, Br, I atoms or groups, except when R′ is H.
11. Compounds according to claim 1 , wherein they are in the form of prodrugs.
12. A pharmaceutical composition, wherein it contains a compound according to claim 1 in combination with pharmaceutically acceptable carriers and/or adjuncts.
13. A method of treatment of diseases of mammals comprising the step of administering to said mammal a therapeutically effective amount of said compound according to claim 1 causing a modulation of the activity of DPI and/or DP I-like enzymes of said mammal.
14. The method according to claim 13 , wherein said modulation comprises the inhibition of DP I and/or DP I-like enzymes.
15. The treatment method according to claim 14 wherein the diseases to be treated are selected from the group consisting of malignant cell degeneration, immune diseases and metabolic diseases of humans.
16. The method according to claim 14 wherein the desease to be treated is impaired wound-healing in humans.